

# Institutional Investment Memorandum

AimwellBio — Private Intelligence Operating System for  
Biopharma

**\$140B**

Annual outsourced spend SignalFire [6]

**78%**

Execs cite AI trust as adoption barrier

**\$67B**

TAM: Pharma Analytics & Intelligence

**34%**

CAGR: AI in Life Sciences

**CONFIDENTIAL — Qualified Investors Only**

# Executive Summary

**AimwellBio is building the decision infrastructure layer beneath every biopharma organization.**

The company operates a private intelligence operating system that ingests, normalizes, validates, contains hallucinations, delivers role-specific briefings, and compounds institutional memory. No other system does all six. The biopharma intelligence market is \$140B annually in outsourced spend. 78% of executives cite AI hallucination as the primary barrier to adoption. AimwellBio is the first company to solve this with a verified, source-traced intelligence platform.

**The market that cannot verify what is true will pay for the system that can.**

# The Market

---

**The convergence of regulatory acceleration, AI adoption, and compliance risk creates a structural market opening.**

**\$67 Billion.** [Industry analysis]

TAM: Pharma Analytics & Intelligence. The total addressable market for pharmaceutical analytics, competitive intelligence, and regulatory monitoring.

**\$8.4 Billion.** [Market sizing]

SAM: Regulatory & Competitive Intel. The serviceable addressable market for structured regulatory and competitive intelligence services.

**\$1.2 Billion.** [AimwellBio estimate]

SOM: Verified AI Intelligence Layer. The serviceable obtainable market for verified, hallucination-contained AI intelligence infrastructure.

**34% CAGR.** [Industry forecast]

AI in Life Sciences growth rate. The adoption curve is steep, but trust is the bottleneck. First mover in verified intelligence owns the category.

6,400+ US pharma/biotech firms. 48,000+ clinical-stage practitioners. \$4.7M average FDA non-compliance cost.

# The Product

---

**Seven layers of infrastructure that ensure every signal reaching a decision-maker is validated, scored, and traceable.**

## 1 Global Signal Ingestion Grid

ClinicalTrials.gov, FDA/EMA/MHRA/PMDA, PubMed, SEC filings, USPTO/WIPO patents, conference abstracts, news. Continuous real-time + scheduled polling.

## 2 Normalization & Context Engine

Entity recognition, timeline mapping, relationship linking, de-duplication. Clean, structured intelligence graph.

## 3 Truth Validation Engine

Multi-source triangulation. Source weighting: regulator > journal > news > AI inference. Provenance tagging on every claim.

## 4 Hallucination Containment

Cross-check against validated knowledge graph. Flag synthetic/unverifiable claims. No unverified intelligence reaches decision-makers.

## 5 Risk & Signal Scoring

Signal Strength, Confidence Level, Strategic Impact, Time Sensitivity scoring on every intelligence unit.

## 6 Decision Delivery System

Role-based delivery: executive dashboards, BD landscapes, regulatory alerts, R&D briefs.

## 7 Memory & Learning Loop

User feedback and corrections compound continuously. Institutional memory never resets.

# Revenue Architecture

Revenue scales across four tiers with natural expansion from individual to enterprise.

## Tier Structure

### Signal: \$229/mo

Individual practitioners. Functional medicine, specialty clinics, solo practices. Weekly intelligence delivery.

### Shield: \$349/mo

Multi-location practices. Compounding networks, med spa chains. Daily intelligence delivery.

### Command: \$649/mo

R&D and regulatory teams. Clinical operations, regulatory affairs departments. Real-time intelligence.

### Enterprise: \$8,500–\$250,000+/mo

Full organizational deployment. Multi-department pharma, biotech, PE/VC funds, sovereign health ministries. Custom SLA.

**Revenue does not depend on volume. It depends on organizational depth. LTV increases with deployment breadth. Institutional memory creates compounding switching costs.**

# Competitive Landscape

**AimwellBio does not compete with dashboards. It replaces the entire unstructured intelligence supply chain.**

## What AimwellBio Replaces

- **Traditional consulting (\$500–\$2,000/hr).** Non-compounding. Static reports. Knowledge leaves when consultants leave. \$250,000+ per engagement for competitive landscapes.
- **Generic AI tools (ChatGPT, etc.).** No hallucination containment. No source verification. No institutional memory. No compliance trail. Unusable in regulated environments.
- **Market intelligence platforms.** Monitoring without verification. Data without validation. No institutional memory. No hallucination containment. Feature tools, not infrastructure.

**The competitive position is not against any single tool. It is replacing the entire unstructured intelligence supply chain with infrastructure that compounds.**

# The Ask

**AimwellBio is raising selectively from institutional investors who understand infrastructure investing.**

The company is positioned at the intersection of three structural tailwinds: AI adoption in regulated industries, the trust deficit in AI outputs, and the \$140B annual spend on biopharma intelligence. First-mover advantage in verified intelligence infrastructure creates a category-defining position.

**The first company to earn institutional trust in AI-generated biopharma intelligence does not win a feature market. It wins the decision layer.**

## Contact

[investors@aimwellbio.com](mailto:investors@aimwellbio.com)

All inquiries confidential. NDA required for financial projections.

[aimwellbio.com](http://aimwellbio.com)